Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of QINLOCK (ripretinib) versus Sutent (sunitinib) in advanced gastrointestinal stromal tumors after imatinib
2018-001803-35Phase 3Unknown
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Dec 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ripretinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Deciphera Pharmaceuticals. Primary endpoint: Progression-free survival by independent radiologic review. Status: unknown.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2018-001803-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001803-35.